.png)
Every health screening operation has a budget that captures the costs above the waterline — clinician salaries, lab fees, consumables, facility overhead. These are the visible costs, and most centres manage them tightly.
Below the waterline sits a different category of cost: the time spent interpreting results, the days that elapse between a test and a recommendation, the variance in how two clinicians read the same panel, the patients who never come back. These are the costs of running a screening workflow manually. They are usually larger than the costs operators measure, and they rarely appear on a P&L.
This post quantifies four of them: senior clinician interpretation time, turnaround drift, decision-fatigue variance, and referral leakage.
In Asia, the cost of clinician interpretation time is not really about salary lines. It is about a clinical workforce that is structurally too small for the demand it carries.
The supply numbers across the region make this clear. Hong Kong currently has approximately two doctors per 1,000 residents, compared to 2.5 in Singapore, 2.5 in Japan, 3.0 in the United Kingdom and 3.8 in Australia, with the city's Hospital Authority reporting persistent shortfalls and projected gaps widening through 2030. The pattern is regional. The OECD/WHO Health at a Glance: Asia/Pacific 2024, which compiles workforce indicators across 27 economies, shows physician density falling below the OECD average of 3.7 per 1,000 across most of Asia — including higher-income markets like Singapore and Japan.
What that supply gap looks like for individual clinicians is well-documented. A 2025 cross-sectional study of Singapore polyclinic healthcare workers — the first post-pandemic assessment of burnout in the country's public primary care found that doctors reported significantly higher emotional exhaustion than their allied health colleagues, with the surrounding literature consistently identifying heavy workload and short consultation times as the dominant drivers.
Against that backdrop, the cost of manual interpretation in health screening looks very different. Consider a screening centre processing 10,000 cases per year — a realistic figure for most regional providers. If interpreting a single multi-parameter screening report and drafting a personalised recommendation takes a senior clinician 15 minutes — conservative, in our experience — that's 2,500 senior clinical hours absorbed each year by report work. In a Western context that is a salary-line inefficiency. In Asia, where the supply of experienced clinicians is the binding constraint on growth, it is the binding constraint on growth. You cannot simply hire your way out of it; the talent is not available at any reasonable price.
Those 2,500 hours are also the hours not spent on complex cases, specialist consultations, or in-person patient counselling — the work where senior clinical judgment generates the most value, and the work that distinguishes a screening provider from a commodity lab. DARA® was designed to compress this exact step: generating a patient's risk profile and personalised recommendations in seconds, so the limited pool of experienced clinicians can spend their hours on the cases where their judgment matters most.
The second cost compounds the first. The clinical value of a screening result decays with time. The longer the gap between the test and the recommendation, the less likely the patient is to act on it.
A 2023 mixed-methods study of community-based screening in Singapore found that one in four patients who received a referral following screening for diabetes, hypertension or hyperlipidaemia did not return for a doctor's follow-up. International figures are similar: referral compliance after primary-care screening was 63% in the United States and 86% in the Netherlands.
These are referrals that the centre has already paid to generate. Every non-return represents a screening encounter that produced clinical value the patient never received — and downstream revenue the centre never realised.
Turnaround time is the lever. When a result-to-report cycle stretches to 18 calendar days, the centre has added two weekends, intervening clinical visits, and a gradual emotional disengagement on the patient's side. The patient who would have acted in week one often doesn't act at all. We have seen DARA® customers running with attached labs move patients from result to report within hours, and customers relying on outsourced labs compress 18-day cycles to 8 days. The exact reduction depends on the lab arrangement and case mix, but the direction is consistent.
The third cost is harder to see because it varies by hour of day, day of week, and individual clinician — but it is well-documented in the clinical literature. A widely-cited estimate is that internists make an average of 15.7 clinical decisions during each patient visit. A 2025 systematic review of decision fatigue in clinical practice, published in BMJ Family Medicine and Community Health, found that sustained decision-making degrades judgment quality — manifesting as defensive over-ordering of tests, missed flags, and a tendency to default to standard rather than personalised recommendations.
In a high-volume screening setting, this becomes a quality-of-care variance the operator cannot easily measure. Morning reports maylook subtly different from evening reports. A senior consultant's flag rate differs from a junior reviewer's on the same patient profile. The same panel, read on a Tuesday afternoon after a busy clinic, may produce a different recommendation than the same panel read on a Friday morning.
The point is not that clinicians make worse decisions when tired — most don't. The point is that consistency erodes. And in screening, consistency is the product.
DARA®'s analytics engine applies the same gold-standard risk scoring — a portfolio of clinically validated calculators covering cardiovascular disease, diabetes, hypertension, chronic kidney disease, and non-alcoholic fatty liver disease, each using the prediction horizon appropriate to its disease — to every patient, every time. The clinician's judgment still owns the final recommendation. The analytic input simply stops varying.
The fourth cost is the most expensive of the four, and the least measured. Manual referral workflows — typed letters, no status tracking, no closed loop back to the screening record — cause patients to drop out of the network between screening and specialist consultation.
A 2025 scoping review of 181 referral system studies — published in Primary Health Care Research & Development and informing WHO guidance on referral design — found that referral systems that develop informally and without structured coordination consistently generate inefficiencies, coverage gaps, and compromised continuity of care. The structural cause is the same across settings: once a referral leaves the screening centre on paper, the centre loses visibility on whether the patient booked, attended, or received the recommended care.
For a screening provider, every leaked referral is two losses at once: the downstream revenue from the specialist visit (and any associated tests, procedures, or chronic-disease management), and the patient relationship itself. The patient who follows up elsewhere is unlikely to return for next year's screening either.
A tracked digital referral workflow — visible status, structured response templates, and an automatic loop back to the screening record — is one of the lowest-effort, highest-leverage workflow changes a screening operation can make. It is also a core part of how DARA® keeps patients moving through a provider's network.
The four costs above are usually larger than the costs an operator does measure. They share a structural feature: they all scale with volume. A centre running 1,000 screens a year can absorb them. A centre running 20,000 a year cannot.
For most operators, the gap between manual and automated screening workflows is not a 5% efficiency improvement. It is the difference between a service that breaks down quietly at scale and one that compounds. The four hidden costs are why.
Manual screening workflows look affordable on paper because the costs that matter most don't appear there. If you'd like to see how DARA® would change the four cost lines above against your actual screening volume, book a demo — we'll walk through the math with you.
References used in this post
